UNSPSC 51312107: Lodoxamide tromethamine

This classification denotes a mast cell stabilizer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50LV9A548L. European Medicines Agency schedules Lodoxamide trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02964MIG. Lodoxamide tromethamine generally arises in the molecular formula C11H6CLN3O6.2C4H11NO3. The term 'lodoxamide tromethamine' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule lodoxamide tromethamine under HS 29269095 and SITC 51484. As of Q4 2014, LODOXAMIDE TROMETHAMINE remains US FDA's Preferred Term for this commodity. Lodoxamide tromethamine bears US NLM identifiers UMLS ID C0065148 and NCI Concept Code C29160. SMILES: C1C(CC(C(C1NC(=O)C(=O)O)CL)NC(=O)C(=O)O)C#N.C(C(CO)(CO)N)O.C(C(CO)(CO)N)O.

UNSPSC 51312107 Lodoxamide tromethamine is a Commodity code that in practice covers a much broader range of pharmaceutical and health-supply procurement than the specific active pharmaceutical ingredient named in the code. State and local governments use this code—or codes nominally beneath it—to solicit generic pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems for public health, community health, and emergency response programs. The solicitations show that issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across multiple states including Oregon). The work involves competitive bidding for pharmaceuticals and health supplies with specific compliance requirements—cGMP certification, Drug Supply Chain Security Act adherence, FDA compliance, E-Verify employment eligibility verification, and insurance coverage ranging from workers' compensation to commercial general liability and professional liability policies.

Recent activity spans Florida, Texas, and Minnesota-administered multi-state cooperative purchasing. Representative solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription models for therapeutic pharmacy initiatives; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026) soliciting generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with evaluations weighted 75 percent on price competitiveness and 25 percent split among fixed pricing, administrative compliance, EDI capability, and administrative fee acceptance. Vendors must maintain contractual relationships with designated wholesalers, comply with performance penalties for late reporting or missed onboarding, and accept administrative fees (MMCAP requires 3 percent) or fixed pricing structures negotiated with individual jurisdictions.